Centrum Medyczne Ad-Med Sp. z o.o.

Research site

Poland Ul. Wladyslawa Syrokomli 1, 51-141 Wroclaw, Poland

Lyme disease · Meningococcal infection
Adults and children

About Specializations

Centrum Medyczne Ad-Med Sp. z o.o. in Wroclaw, Poland specialises in clinical trials of conditions such as Lyme disease, Meningococcal infection, and other specialisations. This site conducts important research.

Main research areas of the site

Bacterial Infections and Mycoses

The research site concentrates on vaccine development for serious bacterial threats, with a special emphasis on meningococcal infection in infants and toddlers, evaluating the MenACYW conjugate vaccine and its immune response.

Immunogenicity assessment of a conjugate vaccine
Safety monitoring in healthy young participants
Head‑to‑head comparison with an existing vaccine
Antibody response to serogroups A, C, W, and Y
Non‑inferiority study design

Centrum Medyczne Ad-Med offers a supportive setting for healthy volunteers and aims to strengthen preventive measures against meningococcal disease.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location

Ul. Wladyslawa Syrokomli 151-141 WroclawPoland

Open in maps ↗

Recruiting now: no trials
Conditions studied: 2

More sites in Wroclaw Poland

All trials

Ongoing trials

Clinical trials registered at this site – none is enrolling right now.

Quick filters

2 clinical trials

Lyme disease

Not recruiting

Study on the Effectiveness and Safety of the VLA15 Vaccine for Preventing Lyme Disease in Healthy Individuals Aged 5 and Older

Registered drug

Study on the Effectiveness and Safety of the VLA15 Vaccine for Preventing Lyme Disease in Healthy Individuals Aged 5 and Older

Registered drug

Poland

Participants:0–17 years · 18–64 years · 65+ years · Healthy volunteers
Substances:BORRELIA BURGDORFERI, SEROTYPE 1, OUTER SURFACE PROTEIN A FUSED VIA A LINKER TO BORRELIA BURGDORFERI, SEROTYPE 2, OUTER SURFACE PROTEIN A
Sponsor:Pfizer Inc.

Contact Research Centre

Meningococcal infection

Not recruiting

Study on the Safety and Immune Response of MenACYW Conjugate Vaccine Compared to a Drug Combination in Healthy Infants and Toddlers

Registered drugNo placebo

Study on the Safety and Immune Response of MenACYW Conjugate Vaccine Compared to a Drug Combination in Healthy Infants and Toddlers

Registered drugNo placebo

Poland

Participants:0–17 years · Healthy volunteers
Substances:N. Meningitidis Group C (Strain C11) Polysaccharide (De-O-Acetylated) Conjugated To Tetanus Toxoid
Sponsor:Sanofi Pasteur

Contact Research Centre

Is this your site?

Join our network of research sites

Get verified: confirm your contact details and recruitment status with us, appear first on the pages of your trials and receive patient requests directly.

See the offer for sites